Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY

AGOURA HILLS, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
November 16, 2021 08:15 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancers

AGOURA HILLS, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
October 20, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDY

AGOURA HILLS, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology...
October 04, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.

AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed an exclusive licensing agreement on September 30, 2021,...
September 01, 2021 12:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.

AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101...
August 24, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

PULMOHEAL™/ ARTIVEDA™ IS CLINICALLY ACTIVE AGAINST MILD AND MODERATE COVID-19.

AGOURA HILLS, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19,...
August 16, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC AND GOLDEN MOUNTAIN PARTNERS FORMING A JOINT VENTURE FOR IPO

AGOURA HILLS, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and COVID-19...
June 15, 2021 09:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC CLOSES COVID-19 CLINICAL TRIAL EARLY.

AGOURA HILLS, California, June 15, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic" or the “Company”), a leading developer of TGF-β therapeutics for oncology,...
May 04, 2021 07:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Joins Chopra Foundation and Heart Foundation of India to Provide Relief for India's Explosive 2nd Wave of Covid.

AGOURA HILLS, California, May 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic"), a leading developer of TGF-β therapeutics for oncology and infectious disease and...
April 20, 2021 12:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC THERAPEUTICS, INC. ANNOUNCES POSITIVE TOP LINE DATA FOR ARTI-19 CLINICAL TRIAL EVALUATING PULMOHEAL™ VERSUS COVID-19.

AGOURA HILLS, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right